Celltrion said on the 27th that it has launched Omriclo (ingredient name omalizumab), a treatment for chronic idiopathic urticaria, in Brazil. Omriclo is the first-mover product, the first omalizumab biosimilar to be launched in Brazil.
In this launch, the 150 mg dose will be sold first, and the 75 mg dose is also scheduled to be added early next year.
Celltrion's Brazil subsidiary took part in the Brazil Allergy and Immunology Association (ASBAI) held in Brazil on the 13th (local time) and introduced Omriclo's clinical data and treatment convenience to local medical staff.
Based on the market performance of existing products, Celltrion aims to ensure the successful market entry of Omriclo and subsequent launches and to expand its product portfolio beyond Brazil to the entire Latin American market.
As of the second quarter, Celltrion's blood cancer treatment Truxima (ingredient name rituximab) recorded about an 80% share in Brazil's private market, and the autoimmune disease treatment Remsima (ingredient name infliximab) holds a 60% share.
Kang Kyung-du, who oversees the Latin America region at Celltrion, said, "Starting with Brazil, from next year we will expand the countries in Latin America where Omriclo is sold and further solidify our position in the market."